Calaspargase Pegol-mknl

Class: Antineoplastic Agents
Chemical Name: [27-Alanine,64-aspartic acid,252-threonine,263-asparagine]-L-asparaginase 2 (EC 3.5.1.1, L-asparagine amidohydrolase II) Escherichia coli (strain K12) tetramer α4, carbamates with α-carboxy-ω-methoxypoly(oxyethylene)
Molecular Formula: C₁₅₁₆H₂₄₂₃N₄₁₅O₄₉₂S₈
CAS Number: 941577-06-6
Brands: Asparlas

Medically reviewed by Drugs.com on Apr 18, 2022. Written by ASHP.

Introduction

Antineoplastic agent; conjugate of monomethoxy polyethylene glycol (mPEG) and Escherichia coli-derived asparaginase.

Uses for Calaspargase Pegol-mknl

Acute Lymphocytic (Lymphoblastic) Leukemia (ALL)

Component of combination chemotherapy for treatment of childhood and young adult ALL. Asparaginase preparations used in induction and/or intensification (consolidation) regimens prior to maintenance therapy; CNS-directed therapy (for prophylaxis of CNS involvement) also required.

In childhood ALL, combination therapy with an asparaginase preparation, a corticosteroid (dexamethasone or prednisone), and vincristine, with or without an anthracycline (daunorubicin or doxorubicin), is used as an induction regimen. Some clinicians reserve 4-drug induction regimens for those with high-risk childhood ALL, while others use such regimens for all patients with childhood ALL regardless of presenting features. Multiple-drug induction regimens produce complete remission in ≥95% of children with ALL.

In adults, induction regimens typically include an anthracycline, vincristine, and prednisone; some regimens also add other drugs (e.g., an asparaginase preparation, cyclophosphamide). Such induction regimens produce complete remission in about 60–90% of adults with ALL.

Adolescents and young adults appear to have better outcomes with use of pediatric-based treatment regimens for ALL instead of traditional adult treatment regimens.

Calaspargase Pegol-mknl Dosage and Administration

General

• Monitor patients for hypersensitivity reactions for 1 hour after administration of calaspargase pegol; be prepared to provide immediate treatment. (See Hypersensitivity under Cautions.)

• Monitor bilirubin, aminotransferase, and glucose concentrations and perform clinical examinations at least weekly until patient recovers from the treatment cycle.

• Consult specialized references for procedures for proper handling and disposal of antineoplastics.

Administration

IV Administration

For solution compatibility information, see Compatibility under Stability.

Administer by IV infusion.

Injection concentrate must be diluted prior to administration.

Administer diluted solution into a running infusion of the same solution (0.9% sodium chloride injection or 5% dextrose injection) used for dilution.

Dilution

Injection concentrate should be clear and colorless. Do not use if cloudy or discolored or if particulate matter is present. Also do not use if injection concentrate has been shaken or vigorously agitated, frozen, or s...